Achondroplasia is a rare, genetic condition that affects bone growth. It is the most common type of skeletal dysplasia. Achondroplasia causes bone growth to slow down, especially in the long bones of the arms and legs. This causes short stature, shortened limbs, and other distinctive features. Genetic variants that cause fibroblast growth factor receptor 3 (FGFR3) overactivity can lead to skeletal conditions such as achondroplasia. QED Therapeutics are studying whether an investigational agent (infigratinib) has the potential to improve the irregular bone growth in achondroplasia by directly impacting FGFR3 overactivity, the underlying cause of the condition.

Infigratinib is not currently approved for the treatment of achondroplasia by the U.S. Food and Drug Administration (FDA) or any other health authority. It